Personalizing the timing of SCT in patients with myelofibrosis

Personalizing the timing of SCT in patients with myelofibrosis

02:13 |

Related Videos

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

5:11

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

3:08

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

Frontline treatment for CLL: the changing paradigm

1:31

Frontline treatment for CLL: the changing paradigm

The future of CLL treatment: aiming for long-lasting remission

1:42

The future of CLL treatment: aiming for long-lasting remission

The use of outpatient cilta-cel in the treatment of multiple myeloma

1:36

The use of outpatient cilta-cel in the treatment of multiple myeloma

Biomarker-guided treatment of CLL in the chemo-free era

6:54

Biomarker-guided treatment of CLL in the chemo-free era

Trials of interest in newly diagnosed myeloma presented at IMS 2024

3:48

Trials of interest in newly diagnosed myeloma presented at IMS 2024

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

1:38

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

Treatment-free remission after second-generation TKI treatment in CML

1:01

Treatment-free remission after second-generation TKI treatment in CML

The tests that are needed to make a definitive diagnosis of CLL

2:59

The tests that are needed to make a definitive diagnosis of CLL

Identifying high-risk myeloma: looking beyond cytogenetic factors

1:18

Identifying high-risk myeloma: looking beyond cytogenetic factors

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

5:21

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion

1:55

Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion

The diagnosis and management of MDS/MPN with neutrophilia (atypical CML)

1:15

The diagnosis and management of MDS/MPN with neutrophilia (atypical CML)

Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions

1:25

Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions

The role of asparaginase in the treatment of ALL

3:02

The role of asparaginase in the treatment of ALL

Mechanisms of resistance to the TKI asciminib in CML

1:16

Mechanisms of resistance to the TKI asciminib in CML

Challenges in risk stratifying LR-MDS: insights into genetic upstaging and early transplant

1:13

Challenges in risk stratifying LR-MDS: insights into genetic upstaging and early transplant

Early detection and interception across hematological cancers

0:44

Early detection and interception across hematological cancers

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics

1:14

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics